Document ID: chunk:federal_register_of_legislation:F2025C00124:reg:8:p2
Version: federal_register_of_legislation:F2025C00124
Segment Type: reg
Provision Reference: reg 8 (pt 2/2)
Character Range: 24602–25594

patient for an HSD pharmaceutical benefit that has a drug that is a medication for the treatment of hepatitis C if the person:
 (a) is, or is to be treated as, an eligible person; and
 (b) is receiving medical treatment by an authorised nurse practitioner in, at or from a private hospital.

Persons receiving HSD pharmaceutical benefits that have drugs that are community access medications
 (6) A person is an eligible patient for an HSD pharmaceutical benefit if:
 (a) the benefit has a drug that is a community access medication; and
 (b) the person is, or is to be treated as, an eligible person.

EFC patient
 (7) A person is an EFC patient for an HSD pharmaceutical benefit that has a UNAR drug if the benefit is or will be prescribed to the person:
 (a) in accordance with the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024; or
 (b) for the purposes of chemotherapy treatment for cancer.

Division 2—Supplies of HSD pharmaceutical benefits from hospitals